404 related articles for article (PubMed ID: 11389076)
21. Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand.
Nishino N; Yoshikawa D; Watanabe LA; Kato T; Jose B; Komatsu Y; Sumida Y; Yoshida M
Bioorg Med Chem Lett; 2004 May; 14(10):2427-31. PubMed ID: 15109626
[TBL] [Abstract][Full Text] [Related]
22. Potent histone deacetylase inhibitors: N-hydroxybenzamides with antitumor activities.
Maeda T; Nagaoka Y; Kuwajima H; Seno C; Maruyama S; Kurotaki M; Uesato S
Bioorg Med Chem; 2004 Aug; 12(16):4351-60. PubMed ID: 15265487
[TBL] [Abstract][Full Text] [Related]
23. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.
Vigushin DM; Ali S; Pace PE; Mirsaidi N; Ito K; Adcock I; Coombes RC
Clin Cancer Res; 2001 Apr; 7(4):971-6. PubMed ID: 11309348
[TBL] [Abstract][Full Text] [Related]
24. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin.
Furumai R; Komatsu Y; Nishino N; Khochbin S; Yoshida M; Horinouchi S
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):87-92. PubMed ID: 11134513
[TBL] [Abstract][Full Text] [Related]
25. Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor.
Payne JE; Bonnefous C; Hassig CA; Symons KT; Guo X; Nguyen PM; Annable T; Wash PL; Hoffman TZ; Rao TS; Shiau AK; Malecha JW; Noble SA; Hager JH; Smith ND
Bioorg Med Chem Lett; 2008 Dec; 18(23):6093-6. PubMed ID: 18954983
[TBL] [Abstract][Full Text] [Related]
26. 2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
Mahboobi S; Sellmer A; Höcher H; Garhammer C; Pongratz H; Maier T; Ciossek T; Beckers T
J Med Chem; 2007 Sep; 50(18):4405-18. PubMed ID: 17691763
[TBL] [Abstract][Full Text] [Related]
27. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
28. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
29. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
[TBL] [Abstract][Full Text] [Related]
30. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity.
Mai A; Massa S; Cerbara I; Valente S; Ragno R; Bottoni P; Scatena R; Loidl P; Brosch G
J Med Chem; 2004 Feb; 47(5):1098-109. PubMed ID: 14971890
[TBL] [Abstract][Full Text] [Related]
31. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
32. N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.
Wang H; Yu N; Song H; Chen D; Zou Y; Deng W; Lye PL; Chang J; Ng M; Sun ET; Sangthongpitag K; Wang X; Wu X; Khng HH; Fang L; Goh SK; Ong WC; Bonday Z; Stünkel W; Poulsen A; Entzeroth M
Bioorg Med Chem Lett; 2009 Mar; 19(5):1403-8. PubMed ID: 19181524
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
Kim DK; Lee JY; Kim JS; Ryu JH; Choi JY; Lee JW; Im GJ; Kim TK; Seo JW; Park HJ; Yoo J; Park JH; Kim TY; Bang YJ
J Med Chem; 2003 Dec; 46(26):5745-51. PubMed ID: 14667227
[TBL] [Abstract][Full Text] [Related]
34. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
35. CHAP31 induces apoptosis only via the intrinsic pathway in human esophageal cancer cells.
Murakami K; Matsubara H; Hoshino I; Akutsu Y; Miyazawa Y; Matsushita K; Sakata H; Nishimori T; Usui A; Kano M; Nishino N; Yoshida M
Oncology; 2010; 78(1):62-74. PubMed ID: 20215787
[TBL] [Abstract][Full Text] [Related]
36. Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4.
Ahn MY; Chung HY; Choi WS; Lee BM; Yoon S; Kim HS
Int J Oncol; 2010 Jan; 36(1):125-31. PubMed ID: 19956841
[TBL] [Abstract][Full Text] [Related]
37. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
Remiszewski SW; Sambucetti LC; Bair KW; Bontempo J; Cesarz D; Chandramouli N; Chen R; Cheung M; Cornell-Kennon S; Dean K; Diamantidis G; France D; Green MA; Howell KL; Kashi R; Kwon P; Lassota P; Martin MS; Mou Y; Perez LB; Sharma S; Smith T; Sorensen E; Taplin F; Trogani N; Versace R; Walker H; Weltchek-Engler S; Wood A; Wu A; Atadja P
J Med Chem; 2003 Oct; 46(21):4609-24. PubMed ID: 14521422
[TBL] [Abstract][Full Text] [Related]
38. Identification of (1H)-pyrroles as histone deacetylase inhibitors with antitumoral activity.
Zubia A; Ropero S; Otaegui D; Ballestar E; Fraga MF; Boix-Chornet M; Berdasco M; Martinez A; Coll-Mulet L; Gil J; Cossío FP; Esteller M
Oncogene; 2009 Mar; 28(11):1477-84. PubMed ID: 19169274
[TBL] [Abstract][Full Text] [Related]
39. The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of Matrigel.
Kuwajima A; Iwashita J; Murata J; Abe T
Anticancer Res; 2007; 27(6B):4163-9. PubMed ID: 18225587
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents.
Guandalini L; Cellai C; Laurenzana A; Scapecchi S; Paoletti F; Romanelli MN
Bioorg Med Chem Lett; 2008 Sep; 18(18):5071-4. PubMed ID: 18723349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
